Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699512 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL21071644 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL21069640 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL1261192 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25695638 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL23728812 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL320644 | 0.97 | MEN1 (0.51) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25194819 | 0.95 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL13137474 | 0.94 | MEN1 (0.44) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL14264537 | 0.94 | MEN1 (0.44) | MEN1KMT2AGAATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025121943-A1 | CANCER CELL-TARGETING DRUG DELIVERY CARRIER COMPRISING CAMPTOTHECIN-IRGD CONJUGATE, AND MANUFACTURING METHOD THEREFOR | 순천향대학교 산학협력단 | 2025-06-12 | — | — | WO | claimed |
| CN-117695219-A | X-ray radiation responsive proteolytic targeting chimeric nano micelle and preparation method and application thereof | 中国药科大学 | 2024-03-15 | — | — | CN | claimed |
| CN-117362391-A | Polypeptide coupled protein degradation targeting chimeric compound for targeted degradation of BRD4, intermediate, preparation method and application | 上海大学 | 2024-01-09 | — | — | CN | claimed |
| CN-120590466-B | Compound of targeted fibroblast activation protein and application thereof | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 2026-05-12 | — | — | CN | disclosed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-121574171-A | Difunctional protein degradation agent of direct targeting proteasome, preparation method and application thereof | 浙大城市学院 | 2026-02-27 | — | — | CN | disclosed |
| EP-4227300-B1 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20250346895-A1 | GENETIC SEQUENCE-CARBOHYDRATE CONJUGATES FOR ENHANCED LIVER- AND KIDNEY-SPECIFIC TARGETING | UNIV CONNECTICUT (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | GENENTECH, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20140128327-A1 | DENDRIMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2660249-A1 | PEPTIDE DERIVATIVE AND USE THEREOF | Kyoto University (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8445528-B2 | Dendrimer conjugates | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120277376-A1 | DENDRIMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-01 | — | — | US | disclosed |
| US-8252834-B2 | Dendrimer conjugates | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100160299-A1 | DENDRIMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100015058-A1 | RADIOLABELED BBN-RGD HETERODIMERS FOR CANCER TARGETING | STANFORD UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090287005-A1 | DENDRIMER CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-19 | — | — | US | disclosed |
| US-20080267882-A1 | Multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide; positron emission tomography; angiogenesis; kits | STANFORD UNIVERSITY (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885GAA 1234/4885 |
| US-20250346895-A1 | GENETIC SEQUENCE-CARBOHYDRATE CONJUGATES FOR ENHANCED LIVER- AND KIDNEY-SPECIFIC TARGETING | B3GAT3, UGGT1, GYS2 | MEN1 2449/4885KMT2A 3308/4885GAA 51/4885 |
| US-20090287005-A1 | DENDRIMER CONJUGATES | CD44, DDOST, ADGRE5 | MEN1 983/4885KMT2A 1693/4885GAA 595/4885 |
| US-20140128327-A1 | DENDRIMER CONJUGATES | CD44, DDOST, ADGRE5 | MEN1 983/4885KMT2A 1693/4885GAA 595/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | MEN1 3715/4885KMT2A 2204/4885GAA 640/4885 |
| US-20100160299-A1 | DENDRIMER CONJUGATES | CD44, DDOST, ADGRE5 | MEN1 983/4885KMT2A 1693/4885GAA 595/4885 |
| US-12440706-B2 | Conjugated chemical inducers of degradation and methods of use | ADRM1, SSB, FCER2 | MEN1 4419/4885KMT2A 4147/4885GAA 363/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | MEN1 1998/4885KMT2A 1480/4885GAA 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.